DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,367 filers reported holding DANAHER CORPORATION in Q1 2019. The put-call ratio across all filers is 1.02 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $183,016 | 0.0% | 762,568 | 0.0% | 0.76% | 0.0% |
Q2 2023 | $183,016 | -8.3% | 762,568 | -3.7% | 0.76% | -24.2% |
Q1 2023 | $199,508 | -23.4% | 791,574 | -21.5% | 1.00% | -26.2% |
Q4 2022 | $260,519 | -99.9% | 1,008,630 | 0.0% | 1.36% | 0.0% |
Q3 2022 | $260,519,000 | +8.3% | 1,008,630 | +6.3% | 1.36% | +12.5% |
Q2 2022 | $240,564,000 | -11.3% | 948,894 | +2.7% | 1.21% | +21.0% |
Q1 2022 | $271,132,000 | +40.0% | 924,324 | +57.1% | 1.00% | +65.2% |
Q4 2021 | $193,629,000 | +5.7% | 588,520 | -2.2% | 0.61% | -9.8% |
Q3 2021 | $183,191,000 | -45.8% | 601,733 | -52.3% | 0.67% | +10.2% |
Q2 2021 | $338,205,000 | +13.3% | 1,260,264 | -5.0% | 0.61% | +1.0% |
Q1 2021 | $298,454,000 | -78.7% | 1,325,988 | +14.2% | 0.60% | +1.2% |
Q4 2020 | $1,398,246,000 | +553.8% | 1,160,808 | +16.9% | 0.60% | -5.4% |
Q3 2020 | $213,867,000 | -2.2% | 993,208 | -19.7% | 0.63% | -13.2% |
Q2 2020 | $218,690,000 | +174.0% | 1,236,726 | +114.4% | 0.73% | +8.8% |
Q1 2020 | $79,824,000 | +3.7% | 576,718 | +15.0% | 0.67% | +37.2% |
Q4 2019 | $76,961,000 | +0.5% | 501,444 | -5.4% | 0.49% | -13.3% |
Q3 2019 | $76,574,000 | +7.8% | 530,185 | +6.6% | 0.56% | +2.2% |
Q2 2019 | $71,051,000 | +30.6% | 497,137 | +20.6% | 0.55% | +22.8% |
Q1 2019 | $54,413,000 | +25.8% | 412,162 | -1.7% | 0.45% | -6.9% |
Q4 2018 | $43,243,000 | -17.8% | 419,343 | -13.4% | 0.48% | +20.9% |
Q3 2018 | $52,627,000 | +17.1% | 484,326 | +6.4% | 0.40% | +1.8% |
Q2 2018 | $44,925,000 | -7.7% | 455,264 | -8.5% | 0.39% | -13.1% |
Q1 2018 | $48,699,000 | -9.1% | 497,383 | -13.9% | 0.45% | -1.7% |
Q4 2017 | $53,593,000 | -13.5% | 577,386 | -20.0% | 0.46% | -18.5% |
Q3 2017 | $61,935,000 | +1.3% | 722,026 | -0.3% | 0.56% | -4.7% |
Q2 2017 | $61,131,000 | -8.2% | 724,380 | -7.0% | 0.59% | -1.8% |
Q1 2017 | $66,625,000 | +2.2% | 778,967 | -7.0% | 0.60% | -7.0% |
Q4 2016 | $65,194,000 | +19.5% | 837,546 | +20.3% | 0.65% | +0.2% |
Q3 2016 | $54,571,000 | +458.3% | 696,138 | +445.2% | 0.64% | +360.7% |
Q2 2016 | $9,774,000 | -23.0% | 127,680 | -4.6% | 0.14% | -33.6% |
Q1 2016 | $12,699,000 | +24.9% | 133,868 | +22.3% | 0.21% | +12.8% |
Q4 2015 | $10,167,000 | +32.8% | 109,466 | +21.8% | 0.19% | +21.4% |
Q3 2015 | $7,657,000 | -3.8% | 89,858 | -3.3% | 0.15% | +49.5% |
Q2 2015 | $7,957,000 | -3.4% | 92,958 | -4.2% | 0.10% | -1.9% |
Q1 2015 | $8,239,000 | -3.8% | 97,041 | -2.9% | 0.10% | +2.9% |
Q4 2014 | $8,567,000 | -12.6% | 99,954 | -22.5% | 0.10% | -70.2% |
Q3 2014 | $9,799,000 | -43.9% | 128,958 | -41.8% | 0.34% | +71.9% |
Q2 2014 | $17,452,000 | +7.7% | 221,671 | +2.6% | 0.20% | -22.3% |
Q1 2014 | $16,207,000 | +16.0% | 216,097 | +19.4% | 0.26% | +21.3% |
Q4 2013 | $13,974,000 | +23.3% | 181,017 | +10.8% | 0.21% | +15.9% |
Q3 2013 | $11,330,000 | +30.7% | 163,438 | +19.4% | 0.18% | +13.0% |
Q2 2013 | $8,667,000 | – | 136,914 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |